Aesica concentrates investment in German formulations business

Zwickau site introduces roller compaction unit for dry granulation production

Aesica Pharmaceuticals, a UK-headquartered pharmaceutical contract development and manufacturing organisation (CDMO), with plants in the UK, Germany and Italy, is adding additional services in its oral solids capability, including a new roller compaction unit for dry granulation production in Zwickau, Germany, after identifying dry granulation as a key growth area within its domestic market.

No financial details have been revealed, but the company says this latest investment compliments other recent investments in Germany, including a new tablet coater capability and pouch packing line.

The roller compaction unit uses a continuous production step that enhances product uniformity and has been installed following demand for pharmaceutical formulation technologies that enable the formulation of APIs otherwise inhibited by the presence of water.

Ian Muir, Managing Director, Finished Dose at Aesica, said: 'This new investment aligns with our strategy of investing in our German sites to broaden capabilities, which is expanding our domestic market share within Germany, while allowing us to offer new services to our global customers. The dry granulation capability will drive business growth as customers with moisture-sensitive APIs seek appropriate technologies, and crucially, experienced CDMOs that can deliver their products.'

Companies